Product Information
MEROPENEM IV 1 GM VIAL is a generic product labeled by Hospira Inc., priced at $4.6875 per EA under NDC 00409139122. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Oct 26, 2011. Its Orange Book therapeutic-equivalence code is AP.
Strength
1 g/20mL
Manufacturer
Hospira Inc.NDC
00409139122
Classification
Generic
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Route
INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
MEROPENEMApproval Type
Generic (ANDA)
FDA Application
ANDA091404FDA Approved
10/26/2011
TE Code
AP
On Market Since
10/9/2019
Pharmacological Classes
Price Statistics
The NADAC for MEROPENEM IV 1 GM VIAL has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 19.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.6875 per EA |
|---|---|
| All-time high | $7.6153 (Nov 13, 2024) |
| All-time low | $4.6687 (Aug 19, 2026) |
| 52-week high | $5.8381 |
| 52-week low | $4.6687 |
| Median price | $5.7000 |
| Average price | $5.7914 |
| Largest weekly change | +15.4% (Oct 23, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hospira Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Meropenem market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Penem Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEROPENEM IV 1 GM VIAL?
The current National Average Drug Acquisition Cost (NADAC) for MEROPENEM IV 1 GM VIAL, manufactured by Hospira Inc., is $4.6875 per EA (NDC 00409139122), effective Sep 30, 2026.
How has the price of MEROPENEM IV 1 GM VIAL changed over time?
Over the history we have for it, the NADAC for MEROPENEM IV 1 GM VIAL has declined 19.6%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for MEROPENEM IV 1 GM VIAL?
Since Apr 17, 2024, the NADAC for MEROPENEM IV 1 GM VIAL has ranged from a low of $4.6687 (Aug 19, 2026) to a high of $7.6153 (Nov 13, 2024), with a median of $5.7000 per EA.
Are there cheaper alternatives to MEROPENEM IV 1 GM VIAL?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as MEROPENEM IV 1 GM VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures MEROPENEM IV 1 GM VIAL?
MEROPENEM IV 1 GM VIAL (NDC 00409139122) is labeled by Hospira Inc., and CMS classifies it as a generic product.